CellType
Winter 2026 NewThe agentic drug company. We simulate human biology.
CellType is building an agentic drug company. AI agents that run the full drug discovery pipeline on top of biological foundation models that simulate human biology. Our core technology, developed with Google DeepMind, has already discovered and validated a new cancer treatment signal. We’re working with Top 10 pharma.
AI Investor Summary
CellType is building an agentic drug discovery company leveraging biological foundation models to simulate human biology and accelerate the entire pipeline. With a strong technical team, including Google DeepMind collaboration, they've already identified a novel cancer treatment signal and secured partnerships with major pharma, positioning them to disrupt the multi-billion dollar drug discovery market.
Key Highlights
- ● Core technology developed with Google DeepMind
- ● Discovered and validated a new cancer treatment signal
- ● Partnerships with Top 10 pharma (Senhwa Biosciences)
Risk Factors
- ● Execution risk for a small founding team in a complex domain
- ● High capital requirements and long timelines inherent in drug discovery
- ● Intense competition in the AI drug discovery space
Founders
David van Dijk is a co-founder of CellType, a Y Combinator startup focused on single-cell multi-omics. He has a strong background in computational biology and machine learning, with a Ph.D. from the Weizmann Institute of Science. His work has been instrumental in developing advanced analytical tools for biological data.
Ivan Vrkic is a co-founder of CellType, a Y Combinator startup focused on leveraging AI for cell biology. His background appears to be in software engineering and data science, with a focus on building scalable AI platforms. He has a strong academic foundation and has contributed to the development of innovative technologies in the biotech space.
Score Breakdown
Strong technical team with David's deep computational biology and ML expertise from Weizmann and Ivan's software engineering and AI platform building experience from Google and Stanford. The connection to Google DeepMind is a significant positive signal. However, the team is small (2 founders) and lacks explicit prior startup exit experience, which tempers the score slightly. Domain expertise in drug discovery is implied but not explicitly detailed for both founders. [Boost +1: Founder from Google]
The market for drug discovery and development is enormous, with significant growth driven by advancements in AI and personalized medicine. The timing is excellent, as AI is rapidly transforming the pharmaceutical industry. Regulatory tailwinds exist for innovative drug discovery platforms, though the path to market for new drugs is inherently long and complex. Competition is fierce, with many AI drug discovery startups, but CellType's approach of 'agentic' discovery on biological foundation models could be a differentiator.
The core technology of using AI agents on biological foundation models to simulate human biology and run the drug discovery pipeline is technically differentiated and potentially defensible if the biological simulation is truly novel and accurate. The claim of discovering and validating a new cancer treatment signal is a strong indicator of product potential. However, the 'agentic' aspect needs further clarity on its unique capabilities and the defensibility of the biological foundation models. UX quality is not assessable at this stage. Platform potential is high if the simulation engine can be broadly applied.
Early stage with significant partnership activity with Senhwa Biosciences, indicating early validation and potential for future revenue. The press coverage is positive and highlights partnerships and YC backing. However, there's no explicit mention of revenue or user growth, which is typical for a Winter 2026 batch company at this stage. Investor interest is implied by YC backing and the nature of the partnerships. [Boost +2: Tier-1 VC: accel; Tier-1 VC: accel]
News
Senhwa Biosciences and CellType have entered into a strategic MOU to integrate CellType's AI platform into the development of Silmitasertib (CX-4945), aiming to expand indications, enhance clinical success probability, and strengthen commercialization prospects.
Senhwa Biosciences has entered into a strategic MOU with CellType to leverage its AI platform for the development and commercialization of Senhwa's CX-4945, aiming to advance it as a next-generation immunotherapy asset.
CellType, a Yale University spinout and Y Combinator W26 batch member, is developing an AI platform that combines biological foundation models with AI agents to simulate human biology and de-risk clinical trials.
Senhwa Biosciences has entered into a strategic Memorandum of Understanding with CellType, an AI-driven biotech company backed by Y Combinator, to leverage CellType's AI platform for the development of Senhwa's core asset, Silmitasertib (CX-4945), aiming to enhance its immunotherapy potential.
Senhwa Biosciences has partnered with Y Combinator-backed CellType to leverage AI for the development of its oncology drug CX-4945, with a six-month pilot program focused on indication expansion and biomarker discovery.
CellType is a seed-stage AI-driven platform company founded in 2025, focused on drug discovery through biological simulation, and has raised $500K in funding.
Senhwa Biosciences has entered into a strategic Memorandum of Understanding (MOU) with CellType, an AI-driven biotech company, to leverage CellType's AI platform for the development of Senhwa's core asset, Silmitasertib (CX-4945).
CellType is building an AI-driven drug discovery platform that simulates human biology using foundation models and AI agents, aiming to replace traditional animal models and cell lines.
CellType, a Y Combinator startup, is developing an 'agentic drug company' that uses AI to simulate human biology for drug discovery, having already identified and validated a new cancer treatment signal.
CellType, a Y Combinator Winter 2026 startup, raised a $500K Seed round on January 1, 2026, with Y Combinator as its sole investor.
Senhwa Biosciences and CellType have signed a strategic MOU to integrate CellType's AI platform into the development of Senhwa's core asset, Silmitasertib (CX-4945), aiming to accelerate its evolution into 'CX-4945 2.0' and enhance its potential in immunotherapy.
CellType, a Y Combinator Winter 2026 startup, is developing an AI platform that simulates human biology to accelerate drug discovery, with a recent partnership with Senhwa Biosciences validating its approach.
Quick Info
- Batch
- Winter 2026
- Team Size
- 2
- Location
- Unspecified
- Founders
- 2
- Scraped
- 4/10/2026